Halozyme Therapeutics (HALO) 2024 Wells Fargo Healthcare Conference summary

Business overview and technology

• Focuses on transforming IV biologics into subcutaneous injections using ENHANZE, improving patient experience and convenience.

• Eight approved products with two more expected by mid-next year, expanding into oncology, immunology, inflammation, and neurology.

• Large safety database and strong commercial acceptance differentiate the platform.

Financial performance and growth outlook

• Profitable since 2019, with five-year CAGR projections: total revenue 16%, royalty revenue 20%, adjusted EBITDA 25%.

• Royalty revenue for 2024 projected at $520M–$555M, aiming for $1B in 2027.

• Wave three product launches expected to drive significant near-term revenue.

Product pipeline and market expansion

• Wave three includes Vyvgart Hytrulo, Opdivo, Ocrevus, Tecentriq, and amivantamab, targeting a $35B addressable market by 2028.

• All wave three products are de-risked, either approved or with positive phase III data.

• Upcoming regulatory milestones: Ocrevus (Sep 13), Tecentriq (Sep 15), Opdivo (Dec 29), amivantamab (mid-next year).